Pricing Log in Create free account

Kairos Pharma, Ltd. (KAPA) vs Oragenics, Inc. (OGEN)

Kairos Pharma, Ltd. and Oragenics, Inc. are both Biotechnology companies. Kairos Pharma, Ltd. is the larger, with a market value of $2.3M against $2.0M — 1.2× the size. Kairos Pharma, Ltd. has negative trailing earnings, so its P/E is not meaningful; Oragenics, Inc. trades at 0.4×. Across the 9 metrics below, Kairos Pharma, Ltd. leads on 5 and Oragenics, Inc. on 4.

Valuation

Metric KAPA OGEN Biotechnology median
P/E n/m 0.38 8.50
P/S n/m 15.40 9.71
P/B 0.44 0.52 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.14 n/m 0.64
EV/Sales n/m 3.56 9.21
Earnings yield (326.58%) 259.93% (33.15%)
Free cash flow yield (216.16%) (534.75%) (25.50%)

Profitability

Metric KAPA OGEN Biotechnology median
Gross margin — 19.89% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (113.96%) (1,307.07%) (56.36%)
Return on assets (104.32%) (264.23%) (48.04%)
Return on invested capital (322.91%) 0.00% 0.00%

Growth

Metric KAPA OGEN Biotechnology median
Revenue growth (TTM) — (75.08%) 6.02%
EPS growth (last fiscal year) (30.44%) 90.51% 30.26%
Revenue growth, 5-year CAGR — (50.98%) 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KAPA OGEN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.98 3.01 4.72
Net debt to EBITDA 1.65 0.98 0.96

Dividend

Metric KAPA OGEN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KAPA OGEN Biotechnology median
Market cap 2.27m 1.97m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack